INDBInternet News Database 2.5 Updated 1 min ago · 315 sources Show or hide images Light or dark

Colon Cancer OS Rates High with Neoadjuvant Immunotherapy

Save Like Comments Compare coverage

Summary

In patients with locally advanced mismatch repair-deficient colon cancer taking neoadjuvant nivolumab plus ipilimumab, no recurrences or deaths occurred after nearly five years. Medscape Medical News

Description from Medscape.

Who is covering this

  1. Medscape Center Factuality: Mostly factual US
    Colon Cancer OS Rates High with Neoadjuvant Immunotherapy

    In patients with locally advanced mismatch repair-deficient colon cancer taking neoadjuvant nivolumab plus ipilimumab, no recurrences or deaths occurred after nearly five years. Medscape Medical News

Comments

Comments need JavaScript.